Back to News
Market Impact: 0.12
Rosalind Franklin University Helix 51 Company Saros Therapeutics Receives Second $2 Million Award to Advance Cancer Immunotherapy
Source: PR Newswire
Healthcare & BiotechPrivate Markets & Venture
Saros Therapeutics received its second National Cancer Institute Phase II award, worth approximately $2 million, to advance its cancer-focused development program. The non-dilutive funding supports an early-stage biomedical incubator company but is unlikely to have broad market implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Broadcom, Amazon Test Limits of Investor Demand for AI Buildout
- Your health insurance premiums may take a big jump in 2027 — here's why
- September Jobs Miss Shocks Markets
- Anthropic to invest $100 million to train AI engineer talent
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s